HLA-E Allelic Genotype Linked to Early Progression in CLL

Share this content:
HLA-E alleles correlate with HLA-E plasma levels and are associated with early disease progression among patients with chronic lymphocytic leukemia.
HLA-E alleles correlate with HLA-E plasma levels and are associated with early disease progression among patients with chronic lymphocytic leukemia.

Human leukocyte antigen-E (HLA-E) alleles correlate with HLA-E plasma levels and are associated with early disease progression among patients with chronic lymphocytic leukemia (CLL), according to a study published in Cancer.1

HLA-E is a nonclassical major histocompatibility complex class I molecule. Recent evidence suggests that HLA-E predicts advanced tumor stages and disease progression. Although increased HLA-E expression and elevated soluble HLA-E (sHLA-E) plasma levels are associated with a poor prognosis among patients with solid tumors, the role of HLA-E as a biomarker in hematologic malignancies remains unclear.

To assess the impact of HLA-E allelic genotype and HLA-E plasma levels on prognosis of patients with blood cancers, investigators analyzed HLA-E alleles and sHLA-E levels in a cohort of 110 patients with CLL.

Results showed that levels of sHLA-E increased with advanced disease stage and decreased following therapy (P = .01). The researchers also found that both HLA-E*01:03 alleles and high levels of sHLA-E were associated with needing early treatment among patients with CLL (P = .027 and P = .023, respectively).

After controlling for confounding factors, the study demonstrated that the presence of at least 1 HLA-E*01:03 allele was independently predictive of requiring early treatment.

RELATED: Next Generation Sequencing Provides More Precise Prognostic Data in CLL

The findings suggest that HLA-E*01:03 status is a promising biomarker for managing patients with CLL. Further studies are warranted to evaluate whether HLA-E/sHLA-E and/or HLA-E alleles can serve as biomarkers for predicting efficacy of treatment strategies targeting the inhibitory receptor of HLA-E in CLL.

Reference

  1. Wagner B, da Silva Nardi F, Schramm S, et al. HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia. Cancer. 2016 Nov 2. doi: 10.1002/cncr.30427 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters